213895-50-2

Upstream product

• 87105-26-8 L-valine N-methylamide 
• 213895-58-0 2,5-di-O-benzyl-L-mannaro-1,4:3,6-di-γ-lactone 
• 128647-50-7 N-benzyloxycarbonyl-L-valine methylamide 
• 22430-23-5 L-mannono-1,4-lactone 
• 213895-35-3 2,5-di-O-benzyl-1,6-di-O-tert-butyldimethylsilyl-3,4-O-isopropylidene-L-mannitol 
• 213895-34-2 1,6-di-O-tert-butyldimethylsilyl-3,4-O-isopropylidene-L-mannitol 
• 213895-37-5 2,5-di-O-benzyl-3,4-O-isopropylidene-L-mannaric acid 
• 213895-36-4 2,5-di-O-benzyl-3,4-O-isopropylidene-L-mannitol 
• 153059-36-0 3,4-O-isopropylidene-L-mannitol 
• 214038-58-1 L-mannaro-1,4:3,6-di-γ-lactone 
• 81927-55-1 O-benzyl 2,2,2-trichloroacetimidate 
• 3496-11-5 2,5-dioxopyrrolidin-1-yl (2S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanoate 

Relevant academic research and scientific papers

Antiviral protease inhibitors

Compounds of the formula I: wherein: A′ and A″ are independently the same or different group of the formula II: wherein: R′ is H. CH3, C(CH3)2, —ORa, —N(Ra)2, —N(Ra)ORa/sup

Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold

A study on the use of derivatized carbohydrates as C2-symmetric HIV-1 protease inhibitors has been undertaken. L-Mannaric acid (6) was bis-O- benzylated at C-2 and C-5 and subsequently coupled with amino acids and amines to give C2-s